The U.S. International Trade Commission (USITC) has announced two new investigations related to China, one on revoking Permanent Normal Trade Relations (PNTR) and the other on government support for the biotech sector.

In a strategic move designed to bolster its bioeconomy, China’s State Council recently approved a new pilot program in the Jiangsu Free Trade Zone (FTZ), which will be used as a testing ground for system-wide innovation in the biopharma sector. One of the core innovations of the plan is

At a meeting last week, the Senate Committee on Homeland Security and Government Affairs considered a bill that would "prohibit contracting with certain biotechnology providers," with four Chinese companies named.